title: Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
abstract: Activated monoamine oxidase (MAO) has a critical role in the pathogenesis of Alzheimer's disease (AD), including the formation of amyloid plaques from amyloid β peptide (Aβ) production and accumulation, formation of neurofibrillary tangles, and cognitive impairment via the destruction of cholinergic neurons and disorder of the cholinergic system. Several studies have indicated that MAO inhibitors improve cognitive deficits and reverse Aβ pathology by modulating proteolytic cleavage of amyloid precursor protein and decreasing Aβ protein fragments. Thus, MAO inhibitors may be considered as promising therapeutic agents for AD.
authors.affiliation: Department of Neurology, The Lu'an Affiliated Hospital of Anhui Medical University, Lu'an People's Hospital, Lu'an, Anhui 237005, P.R. China.
authors.forename: Zhiyou
authors.initials: Z
authors.lastname: Cai
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000818:Animals; D001792:Blood Platelets / Q000201:enzymology; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D004789:Enzyme Activation; D006801:Humans; D058990:Molecular Targeted Therapy; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009410:Nerve Degeneration / Q000201:enzymology; D016874:Neurofibrillary Tangles / Q000201:enzymology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058225:Plaque, Amyloid / Q000201:enzymology
chemical_list: D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D008995:Monoamine Oxidase